Bicocca Open Archive

Logo unimib boa
FONTANA, DILETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.477
AS - Asia 4.795
EU - Europa 4.064
SA - Sud America 761
Continente sconosciuto - Info sul continente non disponibili 430
AF - Africa 125
OC - Oceania 30
Totale 16.682
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.169
SG - Singapore 1.493
IT - Italia 1.475
CN - Cina 963
VN - Vietnam 933
DE - Germania 632
HK - Hong Kong 561
BR - Brasile 559
RU - Federazione Russa 516
IE - Irlanda 277
SE - Svezia 265
CA - Canada 222
GB - Regno Unito 190
FR - Francia 177
IN - India 136
BD - Bangladesh 118
ID - Indonesia 101
FI - Finlandia 100
KR - Corea 100
AR - Argentina 79
IQ - Iraq 78
UA - Ucraina 74
ES - Italia 73
TR - Turchia 73
PL - Polonia 55
JP - Giappone 47
MX - Messico 43
NL - Olanda 43
AT - Austria 41
ZA - Sudafrica 41
CH - Svizzera 39
PK - Pakistan 35
EC - Ecuador 30
SA - Arabia Saudita 25
BE - Belgio 22
PH - Filippine 22
AU - Australia 21
DK - Danimarca 21
UZ - Uzbekistan 21
VE - Venezuela 21
CO - Colombia 20
PE - Perù 20
MA - Marocco 18
CZ - Repubblica Ceca 17
EG - Egitto 13
LT - Lituania 13
IR - Iran 12
TN - Tunisia 11
KE - Kenya 10
PY - Paraguay 10
UY - Uruguay 10
CL - Cile 9
ET - Etiopia 9
AZ - Azerbaigian 8
NI - Nicaragua 7
NP - Nepal 7
NZ - Nuova Zelanda 7
DO - Repubblica Dominicana 6
JO - Giordania 6
KG - Kirghizistan 6
MY - Malesia 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
EU - Europa 5
JM - Giamaica 5
NO - Norvegia 5
AL - Albania 4
DZ - Algeria 4
IL - Israele 4
LY - Libia 4
OM - Oman 4
PA - Panama 4
PS - Palestinian Territory 4
RO - Romania 4
AM - Armenia 3
BG - Bulgaria 3
BM - Bermuda 3
BN - Brunei Darussalam 3
BO - Bolivia 3
CI - Costa d'Avorio 3
GR - Grecia 3
HN - Honduras 3
KZ - Kazakistan 3
MU - Mauritius 3
PT - Portogallo 3
TH - Thailandia 3
CY - Cipro 2
GT - Guatemala 2
HR - Croazia 2
HU - Ungheria 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MM - Myanmar 2
MT - Malta 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
Totale 16.237
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.055
Singapore 841
Ashburn 651
San Jose 580
Milan 543
Hong Kong 534
Frankfurt am Main 413
Ho Chi Minh City 290
Dublin 274
Hanoi 231
Chandler 224
Dallas 213
Los Angeles 205
New York 172
Wilmington 172
Fairfield 167
Beijing 156
Hefei 152
Toronto 142
Houston 138
Santa Clara 123
The Dalles 109
Chicago 105
Dearborn 91
Seoul 90
Munich 84
Woodbridge 84
Seattle 75
Jakarta 71
São Paulo 66
Shanghai 63
Boardman 58
Lauterbourg 56
Princeton 56
Rome 54
Helsinki 53
Buffalo 52
Moscow 46
Cambridge 45
Council Bluffs 44
Da Nang 42
Jacksonville 42
Kent 38
Orem 38
Columbus 37
Warsaw 37
Naples 35
Nuremberg 33
Boyds 31
Montreal 31
Altamura 30
Zurich 30
Guangzhou 29
London 29
Nanjing 29
Tokyo 29
Haiphong 28
Johannesburg 28
Turin 27
Lawrence 26
Chennai 25
Kirkuk 25
Baghdad 24
Biên Hòa 23
Turku 23
Vienna 23
Atlanta 22
Hải Dương 22
Monza 22
Poplar 22
Denver 21
Dong Ket 21
Phoenix 20
Sesto San Giovanni 20
Stockholm 20
Washington 19
Desio 18
Rio de Janeiro 18
Romola 18
Tashkent 18
San Diego 17
Brussels 16
Tianjin 16
Amsterdam 15
Brooklyn 15
Genoa 15
Ha Long 15
Kocaeli 15
Lima 15
Pavia 15
Belo Horizonte 14
Carate Brianza 14
Istanbul 14
Paris 14
Ankara 13
Boston 13
Lappeenranta 13
Salt Lake City 13
Bari 12
Lissone 12
Totale 9.937
Salva come PNG Salva come JPEG
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 619
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 492
Behavior of the anti-apoptotic BCL-2 protein in non-small-cell lung cancer cell models in response to treatments with ALK inhibitors and its potential dual BCL2-ALK inhibition 463
Characterization of the role of mutated ETNK1 in the onset of atypical Chronic Myeloid Leukemia 460
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 458
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 453
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 446
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 425
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 424
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 397
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 389
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 388
Idiopathic erythrocytosis: a germline disease? 384
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 381
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 379
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 350
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 350
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 347
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 330
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review 321
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 318
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 316
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 307
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 301
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 299
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 295
Erratum: Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design (Journal of Medicinal Chemistry (2017) 60:22 (9205-9221) DOI: 10.1021/acs.jmedchem.7b01039) 283
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 277
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 269
Clonal evolution analysis identifies ETNK1 as an early event and SETBP1 as a late event in atypical Chronic Myeloid Leukemia 269
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 267
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 264
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 250
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 249
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 242
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 234
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 229
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 228
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 227
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis 225
Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage 218
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer 211
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 208
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 204
Integrating mutational profiles and single-cell transcriptional data using LASSO regularized regression to elucidate key molecular functions involved in the pathogenesis of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with neutrophilia 200
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer 195
Role of somatic ETNK1 mutation in the mitochondrial activity 195
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 191
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape 190
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 188
ETNK1 mutations increase mitochondrial activity and promote DNA damage through ROS production 176
miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia 173
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 165
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 159
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia 150
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia 133
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer 121
Totale 16.682
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.844
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.844
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022567 0 88 79 61 36 59 21 20 30 43 56 74
2022/20231.152 108 271 124 104 110 152 18 62 64 34 32 73
2023/20241.216 46 43 64 76 122 276 235 36 105 52 51 110
2024/20253.188 149 284 170 172 254 120 222 114 334 576 285 508
2025/20267.644 1.169 544 612 880 704 342 1.118 299 514 671 352 439
2026/2027321 262 59 0 0 0 0 0 0 0 0 0 0
Totale 16.682